Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resting-State Functional Connectivity Alterations in Obsessive-Compulsive Disorder: Relationships Between Connectivity and Clinical Profiles in the Global OCD Study.

Biological psychiatry. Cognitive neuroscience and neuroimaging·2026
Same author

Early adversity links more to transdiagnostic than obsessive-compulsive disorder (OCD)-specific features: Findings from a large multinational study.

Comprehensive psychiatry·2026
Same author

Toward trustworthy clinical AI for obsessive-compulsive disorder: reliability, generalizability, and interpretability of a transformer model across the ENIGMA-OCD consortium.

medRxiv : the preprint server for health sciences·2026
Same author

A study of alcohol dependence in obsessive-compulsive disorder.

Journal of psychiatric research·2026
Same author

Structural brain findings associated with clinical profiles but not diagnosis in unmedicated adults with obsessive-compulsive disorder: the Global OCD study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Executive Function in Obsessive-Compulsive Disorder: A Worldwide Mega-Analysis of Task-Based Functional Neuroimaging Data of the ENIGMA-OCD Consortium.

Biological psychiatry. Cognitive neuroscience and neuroimaging·2026

Related Experiment Video

Updated: Jun 26, 2026

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

Memantine as an augmenting agent for severe pediatric OCD

Dianne M Hezel, Katherine Beattie, S Evelyn Stewart

    The American Journal of Psychiatry
    |February 4, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
    18:01

    Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

    Published on: August 18, 2008

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
    04:29

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

    Published on: January 7, 2019

    Related Experiment Videos

    Last Updated: Jun 26, 2026

    Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
    11:17

    Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

    Published on: November 25, 2025

    Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
    18:01

    Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

    Published on: August 18, 2008

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
    04:29

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

    Published on: January 7, 2019